摘要
[目的]通过大数据分析了解NAT1mRNA和蛋白质在结肠癌中的表达情况及对临床预后的影响。[方法]检索当前世界上几个主要的肿瘤生物信息数据库(Oncomine、TCGA、CPTAC等)中有关NAT1的相关数据,对其进行生物信息学分析,对NAT1在结肠癌中的临床作用进行荟萃分析。[结果]443项有关NAT1的不同类型研究结果纳入Oncomine数据库,NAT1表达在肿瘤与其对照组织中有统计学差异的结果有37项,其中NAT1高表达的有12项,低表达的有25项。涉及到结肠癌的研究共有15项,且在结肠癌组织中均为低表达。涉及到NAT1在结肠癌和正常组织中的mRNA表达的样本共有565例。Oncomine数据库中9项研究数据集的二次分析结果表明NAT1在结肠癌中的表达低于正常组织(P <0.05)。TCGA数据库和CPTAC数据库提示NAT1在结肠癌中的mRNA和蛋白水平均呈现低表达(P <0.05)。另外,免疫组织化学显示NAT1在结肠癌组织中表达较弱或呈阴性,而在正常组织中表达较强或中等。NAT1表达和年龄、种族、性别、体重、肿瘤分期无关,而与肿瘤的组织病理分型可能存在一定相关性(P <0.05)。不仅如此,生存分析发现高表达NAT1的患者预后较好(P <0.05)。[结论]NAT1的mRNA和蛋白水平在结肠癌组织中呈现低表达,和结肠癌不良预后相关。
[Objective] To explore the expression of NAT1 and its clinical significance in colorectal cancer( CRC).[Method]The data related to NAT1 were retrieved from several major tumor bioinformatics databases( Oncomine,TCGA,CPTAC,etc.) in the world. Bioinformatics analysis was carried out to analyze the clinical role of NAT1 in colon cancer.[Result] A total of 443 studies of different types of NAT1 were collected in the Oncomine database. The expression of NAT1 mRNA in 37 studies was statistically significant,of which 12( 0 in CRC) showed increased expression of NAT1 and 25( 15 in CRC) showed decreased expression. Data from 9 studies containing 565 samples in the Oncomine database also showed that the expression of NAT1 was lower in colon cancer than in normal tissues( P < 0. 05). TCGA database and CPTAC database also indicated that NAT1 mRNA and protein expression was under expressed in CRC( P < 0. 05). Furthermore,immunohistochemistry results showed that NAT1 was weakly or negatively expressed in CRC tissues,while it was highly or moderately expressed in normal tissues. There was no correlation between NAT1 protein expression and clinical characteristics,such as age,race,sex,body weight and tumor stage,but significantly correlated with histopathological types of CRC( P < 0. 05). Moreover,survival analysis showed that patients with high expression of NAT1 had a better prognosis( P < 0. 05).[Conclusion]The mRNA and protein levels of NAT1 is under-expressed in CRC,which is associated with the prognosis of CRC.
作者
李丹
余涛
曾智
吴杰
兰昱
宋伟
LI Dan;YU Tao;ZENG Zhi;WU Jie;LAN Yu;SONG Wei(Department of Pharmacy,Renmin Hospital of Wuhan University,Wuhan 430060,China;Integrated Traditional Chinese and Western Medicine Ward of Oncology Department,the Central Hospital of Wuhan,Tongji Medical College,Huazhong University of Science&Techonology,Wuhan 430014,China;Department of Pathology,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《生物技术》
CAS
2021年第5期458-464,507,共8页
Biotechnology
基金
国家自然科学基金项目(81704023
81803789)
吴阶平医学基金会资助项目(320.6750)。
